Do amoxicillin‑clavulanate (Augmentin) and cephalexin (Keflex) adequately cover Escherichia coli in a urinary tract infection?

Coverage of E. coli in UTIs: Augmentin vs Keflex

Augmentin (amoxicillin-clavulanate) provides reliable coverage for E. coli in urinary tract infections and should be considered a reasonable first-line option, while Keflex (cephalexin) is FDA-approved for E. coli UTIs but is not specifically recommended in current major guidelines for empirical therapy.

Augmentin for E. coli UTIs

Augmentin is FDA-labeled for genitourinary tract infections caused by E. coli 1. The drug achieves high urinary concentrations where it demonstrates sustained bactericidal activity against E. coli without resistance emergence 2. Recent molecular studies reveal that the high urinary concentrations of clavulanic acid exert direct antibacterial activity, eradicating resistant subpopulations that might otherwise survive 2.

Efficacy Data

• Overall susceptibility: 82.9-90% of E. coli strains from UTIs are susceptible to amoxicillin-clavulanate 3, 4
• Community-acquired infections: Higher susceptibility rates compared to nosocomial isolates 4
• Most ampicillin-resistant E. coli strains remain susceptible to amoxicillin-clavulanate 4

Important Caveat on Testing Methodology

A critical issue exists with susceptibility testing: NCCLS methodology shows 74% of E. coli susceptible to amoxicillin-clavulanate, while French CA-SFM methodology shows only 13% susceptible for the same isolates 5. This methodological discrepancy means apparent resistance may reflect testing differences rather than true resistance. The NCCLS methodology is more clinically relevant for predicting urinary tract efficacy 5.

Emerging Resistance Concerns

Recent pediatric data from Italy (2019-2020) shows a statistically significant trend toward increasing amoxicillin-clavulanate resistance in E. coli compared to 2015-2018 6. This suggests the need for local antibiogram review before empirical use.

Keflex for E. coli UTIs

Keflex is FDA-approved for genitourinary tract infections caused by E. coli, Proteus mirabilis, and Klebsiella pneumoniae 1. However, notably absent from the 2024 European Association of Urology guidelines is any mention of first-generation cephalosporins like cephalexin for empirical UTI treatment 7.

The EAU guidelines specifically recommend:

• For uncomplicated cystitis: Fosfomycin, nitrofurantoin, or pivmecillinam as first-line 7
• For pyelonephritis: Fluoroquinolones or third-generation cephalosporins (cefpodoxime, ceftibuten) - not first-generation 7

Clinical Algorithm for Selection

For uncomplicated cystitis:

1. First choice: Nitrofurantoin (5 days) or fosfomycin (single dose) 7
2. Alternative if local E. coli resistance <20%: First-generation cephalosporins like cephalexin 7
3. Augmentin: Reasonable alternative when above agents unavailable or contraindicated

For pyelonephritis:

1. Oral therapy: Fluoroquinolones or third-generation oral cephalosporins (cefpodoxime, ceftibuten) 7
2. IV therapy requiring step-down: Ceftriaxone initially, then consider Augmentin if susceptible
3. Avoid cephalexin - not guideline-recommended for pyelonephritis

For complicated UTIs or ESBL-producing E. coli:

• High-dose Augmentin (2875 mg amoxicillin twice daily) can be effective as carbapenem-sparing therapy in select cases 8, 9
• Requires susceptibility confirmation and close monitoring

Critical Pitfalls

1. Do not assume Augmentin resistance based on disk diffusion alone - confirm with MIC testing using NCCLS methodology 5
2. Plasma vs urinary pharmacokinetics matter: Augmentin's efficacy is site-specific due to high urinary clavulanic acid concentrations 2
3. Local resistance patterns are essential: Both agents require <20% local E. coli resistance for empirical use 7
4. Cephalexin is not appropriate for pyelonephritis despite FDA approval for "genitourinary infections" - guidelines specify higher-generation cephalosporins 7